Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV

MLA

Biao Lu, et al. “Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV.” New England Journal of Medicine, vol. 354, Jan. 2006, pp. 251–60. EBSCOhost, https://doi.org/10.1056/nejmoa051871.

APA

Biao Lu, John J. Toole, Andrew K. Cheng, Joel E. Gallant, Rafael Campo, Steven L. Chuck, Anton Pozniak, Brian Gazzard, Jeffrey Enejosa, Edwin DeJesus, Jose R. Arribas, & Damian J McColl. (2006). Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV. New England Journal of Medicine, 354, 251–260. https://doi.org/10.1056/nejmoa051871

Chicago

Biao Lu, John J. Toole, Andrew K. Cheng, Joel E. Gallant, Rafael Campo, Steven L. Chuck, Anton Pozniak, et al. 2006. “Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV.” New England Journal of Medicine 354 (January): 251–60. doi:10.1056/nejmoa051871.